Streetbeat News

Products Services

GLMD

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) has announced a strategic partnership with OnKai to apply its artificial intelligence (AI) models for enrollment and execution of clinical trials in underserved communities. The collaboration will start with Galmed's Primary Sclerosing Cholangitis (PSC) clinical development program. The clinical development for PSC is expected to start with a Phase 2a study in the fourth quarter of 2023. OnKai's AI platform is anticipated to generate a comprehensive enrollment plan for each trial phase and support the trial in local clinics.

Portfolio Pulse from Happy Mohamed

July 10, 2023 | 12:06 pm

BDRX

Biodexa Ltd, a subsidiary of Biodexa Pharmaceuticals, has completed the enrolment and treatment of nine pediatric patients in the ongoing Phase 1 study of MTX-110 in newly diagnosed diffuse midline gliomas.

Portfolio Pulse from Benzinga Newsdesk

July 10, 2023 | 12:06 pm

ICAD

iCAD, Inc. (NASDAQ:ICAD) is showcasing its ProFound AI Suite for breast cancer detection at the AHRA 2023 annual meeting. The suite includes ProFound AI Detection®, ProFound AI® Density Assessment, and ProFound AI® Risk. The company is also offering an ROI tool to help organizations measure the return on investment for adopting ProFound AI. Several healthcare providers, including Midstate Radiology Associates, Kettering Health, and Naugatuck Valley Radiology, have reported increased efficiency, standardized assessments, and improved patient care after adopting iCAD's solutions.

Portfolio Pulse from Happy Mohamed

July 10, 2023 | 12:05 pm

AAPL

SPIKE

Apple Inc. (NASDAQ:AAPL) closed 0.59% lower on Friday, falling back into a rising channel pattern. Despite the retracement, Apple looks set to continue higher in the short term. The company's upcoming release of its $3,500 Vision Pro Headset could inflate bullish Apple trader’s heads. However, the pattern can be bearish in the long term. Ahead of the Federal Reserve’s decision on interest rates, volatility in the stock market may increase. Traders wishing to trade the volatility can use MIAX’s SPIKES Volatility products.

Portfolio Pulse from Melanie Schaffer

July 10, 2023 | 12:05 pm

PRTK

Paratek Pharmaceuticals has announced a modification to its Project BioShield contract with the Biomedical Advanced Research and Development Authority (BARDA). The modification provides new development milestones for the next procurement of NUZYRA, a treatment for pulmonary anthrax. The next procurement will be split into two equal parts based on the achievement of specific development milestones. The first procurement will be triggered by positive data from a dose-ranging efficacy study in 2024. The second procurement will be triggered by positive data from two studies in 2024. The final procurement will be triggered by Paratek's receipt of sNDA approval from the FDA for the treatment of inhalation anthrax.

Portfolio Pulse from Happy Mohamed

July 10, 2023 | 12:04 pm

CNTB

Connect Biopharma has presented additional data from its atopic dermatitis trial in China at the 2023 World Congress of Dermatology. The data, from four poster presentations, detailed the achievement of primary and secondary endpoints, improvements in investigator-rated outcomes, and improvements in patient reported outcomes from the initial 16-week treatment period with rademikibart (formerly known as CBP-201) in patients with moderate-to-severe atopic dermatitis in the pivotal CN002 trial.

Portfolio Pulse from Benzinga Newsdesk

July 10, 2023 | 12:04 pm

BTCUSD

META

TSLA

Major stories from the weekend include Elon Musk's test drive of Tesla's Cybertruck, the potential introduction of a gold-backed currency by BRICS countries, and warnings of a potential recession by U.S. Treasury Secretary Janet Yellen. Additionally, Bitcoin is expected to face a significant test in 2023, and Twitter is struggling to prove that Meta Platform Inc stole trade secrets.

Portfolio Pulse from Benzinga Newsbot

July 10, 2023 | 12:03 pm

MAIA

Maia Biotechnology has announced preliminary survival data from the Part A safety lead-in of its ongoing THIO-101 Phase 2 trial. The trial is evaluating THIO in sequential combination with Cemiplimab in advanced non-small cell lung cancer. The first two patients dosed with THIO have shown no documented progression for 12.2 and 11.5 months, and no new anti-cancer treatment 10.2 and 8.5 months after concluding treatment with THIO.

Portfolio Pulse from Benzinga Newsdesk

July 10, 2023 | 12:02 pm

CNTA

Centessa Pharmaceuticals has announced the dosing of the first subject in its registrational PRESent-2 study, which is evaluating SerpinPC for the treatment of Hemophilia B without inhibitors.

Portfolio Pulse from Benzinga Newsdesk

July 10, 2023 | 12:01 pm

HYZN

Hyzon Motors has announced the completion and factory acceptance testing of its Bingle-Stack 200kW fuel cell system B-samples. This marks a significant milestone in the company's development of hydrogen fuel cell technology.

Portfolio Pulse from Benzinga Newsdesk

July 10, 2023 | 11:46 am